Skip to main content
. Author manuscript; available in PMC: 2021 May 20.
Published in final edited form as: ACS Infect Dis. 2020 Oct 20;6(11):2926–2937. doi: 10.1021/acsinfecdis.0c00368

Figure 5.

Figure 5.

Polycarboxylate nanoparticles (NPs) are well-tolerated by HeLa cells. HeLa cells were treated with different concentrations of (A) HPMCP-55S NPs, (B) Eudragit S100 NPs, (C) Kollicoat MAE 100 NPs, and (D) PVAP NPs for 24 and 48 h. The viability of NP-treated HeLa cells was compared to untreated controls using MTT assay and to obtain % cell viability (data expressed as means ± SEM.; n = 3).